Sign in
Enrolling by invitationEarly phase 1

Stem cell and regenerative treatments for inner ear injury, tinnitus and hearing loss

Tests regenerative therapies, including stem cells, in people with inner ear injury or hearing loss.

Key facts

Who runs it
Truway Health, Inc.
Where
New York, United StatesSee the site
Trial code
Registry title
Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
Status
Enrolling by invitation
Phase
Early phase 1
People taking part
120 people, planned
Started
8 Mar 2026
Expected to end
8 Mar 2099
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Audiologic Monitoring
  • Investigational Regenerative Pharmacologic Therapy
  • Stem Cell Regenerative Therapy
  • Combination Regenerative Therapy
Record updated
16 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with sensorineural hearing loss (inner ear or nerve hearing loss), tinnitus (ringing in the ears) or an inner ear injury. It tests experimental drug, stem cell and combined treatments against standard hearing checks.

Age
18-75 years
Sex
All sexes
Disease stage
A doctor's diagnosis of sensorineural hearing loss, tinnitus or inner ear injury. Hearing threshold ≥25 dB HL at one or more test frequencies.
Earlier treatment
People cannot join if they had experimental hearing regeneration therapy within 12 months. People who had cochlear implant surgery cannot join.

Main reasons for not taking part

  • Active middle ear infection
  • Past cochlear implant surgery
  • Known damage to the hearing nerve or brain pathways beyond the inner ear (retrocochlear pathology)
  • Known pregnancy at enrollment
  • Any medical condition that may affect taking part or safety

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Adults aged 18-75 years
  • Clinical diagnosis of sensorineural hearing loss, tinnitus, or inner ear injury
  • Hearing threshold ≥25 dB HL at one or more audiometric frequencies
  • Ability to complete audiometric testing and follow study procedures
  • Ability to provide informed consent

Who cannot take part

  • Participation in experimental hearing regeneration therapy within 12 months
  • Active middle ear infection
  • History of cochlear implant surgery
  • Any medical condition that may interfere with study participation or safety
  • Known retrocochlear pathology
  • Known pregnancy at time of enrollment

Where in United States

  • Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016New York, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The HEAR-RESTORE study is an exploratory clinical research program designed to evaluate new diagnostic and regenerative approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss. Inner ear disorders can result from acoustic trauma, infections, inflammation, or other conditions that affect the cochlea, auditory nerve, or vestibular system. These conditions may lead to muffled hearing, ringing in the ears (tinnitus), balance disturbances, or reduced hearing sensitivity.

Read full original descriptionShow less

The purpose of this study is to better understand how inner ear injuries develop and to evaluate potential treatments that may support hearing recovery or protect auditory function. Participants will undergo comprehensive ear and hearing evaluations including audiometry, speech recognition testing, tympanometry, and other diagnostic assessments used in audiology and otolaryngology. These tests help measure hearing thresholds, ear pressure, and auditory nerve responses.

The study may also explore emerging regenerative medicine strategies aimed at restoring inner ear function. These approaches may include investigational therapies designed to promote repair of cochlear hair cells, reduce inflammation in the inner ear, or support neural recovery in the auditory pathway. Research may include evaluation of regenerative biological therapies, stem cell-based approaches, and other experimental technologies intended to support recovery of hearing or reduce symptoms such as tinnitus.

Participants will be monitored over time to assess hearing outcomes, safety, and changes in auditory function. Study assessments may include repeat audiology tests, imaging studies, symptom questionnaires, and other clinical measurements used to track hearing health.

The results of this research may contribute to improved diagnostic methods and potential future treatments for individuals with hearing loss or inner ear disorders.

The 4 groups in the trial

  • Standard Audiologic MonitoringExisting treatment, for comparison

    Participants will undergo comprehensive audiologic evaluation and monitoring including pure-tone audiometry, speech recognition testing, tympanometry, and other standard diagnostic assessments used in otolaryngology. This arm serves as the standard-of-care comparison group for evaluating hearing outcomes.

    Treatment: Audiologic Monitoring

  • Regenerative Pharmacologic TherapyTreatment being tested

    Participants will receive investigational pharmacologic therapies designed to support inner ear recovery or protect cochlear hair cells following injury. Audiologic testing and symptom monitoring will be performed throughout the study period to evaluate hearing outcomes and safety.

    Treatment: Investigational Regenerative Pharmacologic Therapy

  • Stem Cell Investigational TherapyTreatment being tested

    Participants will receive investigational regenerative medicine therapies involving stem cell-based approaches intended to support repair of inner ear structures or auditory nerve pathways. Audiometric and clinical monitoring will be conducted to evaluate safety and potential improvements in auditory function.

    Treatment: Stem Cell Regenerative Therapy

  • Combination Regenerative TherapyTreatment being tested

    Participants will receive a combination of investigational regenerative strategies designed to support auditory recovery following inner ear injury. These approaches may include pharmacologic regenerative agents combined with biological or cellular therapies. Participants will undergo comprehensive hearing assessments throughout the study.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Truway Health Inner Ear Regeneration & Hearing Restoration Trial
Plain-language title
Stem cell and regenerative treatments for inner ear injury, tinnitus and hearing lossGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
16 March 2026